Cardiovascular Systems, Inc. to Post Q1 2023 Earnings of ($0.22) Per Share, Zacks Research Forecasts (NASDAQ:CSII)
Cardiovascular Systems, Inc. to Post Q1 2023 Earnings of ($0.22) Per Share, Zacks Research Forecasts (NASDAQ:CSII)
Cardiovascular Systems, Inc. (NASDAQ:CSII – Get Rating) – Zacks Research issued their Q1 2023 earnings per share (EPS) estimates for Cardiovascular Systems in a research report issued on Wednesday, September 28th. Zacks Research analyst D. Dey anticipates that the medical device company will post earnings of ($0.22) per share for the quarter. The consensus estimate for Cardiovascular Systems' current full-year earnings is ($0.67) per share. Zacks Research also issued estimates for Cardiovascular Systems' Q2 2023 earnings at ($0.16) EPS, Q3 2023 earnings at ($0.15) EPS, Q4 2023 earnings at ($0.15) EPS, FY2023 earnings at ($0.68) EPS, Q1 2024 earnings at ($0.18) EPS, Q2 2024 earnings at ($0.11) EPS, Q3 2024 earnings at ($0.18) EPS, Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at ($0.53) EPS and FY2025 earnings at ($0.49) EPS.
心血管系統公司(納斯達克代碼：CSII-GET Rating)-扎克斯研究公司在9月28日星期三發佈的一份研究報告中發佈了他們對心血管系統2023年第一季度每股收益的估計。扎克斯研究公司的分析師D.Dey預計，這家醫療設備公司本季度的每股收益將達到0.22美元。對心血管系統公司目前全年收益的普遍估計是每股0.67美元。扎克斯研究公司還發布了對心血管系統公司2023年第二季度每股收益(0.16美元)、2023年第三季度每股收益(0.15美元)、2023年第四季度每股收益(0.15美元)、2023年第四季度每股收益(0.68美元)、2024年第一季度每股收益(0.18美元)、2024年第二季度每股收益(0.11美元)、2024年第三季度每股收益(0.18美元)、2024年第四季度每股收益(0.07美元)、2024年第四季度每股收益(0.53美元)和2025財年每股收益(0.49美元)的預測。
Cardiovascular Systems Trading Down 1.1 %
心血管系統降價1.1%
Shares of CSII stock opened at $13.86 on Monday. The company has a quick ratio of 5.19, a current ratio of 6.05 and a debt-to-equity ratio of 0.08. The business has a 50-day moving average price of $14.72 and a two-hundred day moving average price of $16.46. Cardiovascular Systems has a 12-month low of $12.51 and a 12-month high of $36.97. The firm has a market cap of $567.77 million, a P/E ratio of -14.59 and a beta of 0.97.
CSII股票週一開盤報13.86美元。該公司的速動比率為5.19，流動比率為6.05，債務權益比率為0.08。該業務的50日移動均線價格為14.72美元，200日移動均線價格為16.46美元。心血管系統公司的12個月低點為12.51美元，12個月高位為36.97美元。該公司市值為5.6777億美元，市盈率為-14.59倍，貝塔係數為0.97。
Institutional Investors Weigh In On Cardiovascular Systems
機構投資者參與心血管系統
Several hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its stake in Cardiovascular Systems by 0.6% during the fourth quarter. Rhumbline Advisers now owns 99,634 shares of the medical device company's stock worth $1,871,000 after purchasing an additional 566 shares during the last quarter. UBS Group AG lifted its stake in shares of Cardiovascular Systems by 6.3% in the 2nd quarter. UBS Group AG now owns 11,500 shares of the medical device company's stock valued at $165,000 after acquiring an additional 679 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Cardiovascular Systems by 32.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,025 shares of the medical device company's stock valued at $68,000 after acquiring an additional 735 shares during the last quarter. Eaton Vance Management lifted its stake in shares of Cardiovascular Systems by 5.4% in the 4th quarter. Eaton Vance Management now owns 14,547 shares of the medical device company's stock valued at $252,000 after acquiring an additional 749 shares during the last quarter. Finally, Perkins Capital Management Inc. lifted its stake in shares of Cardiovascular Systems by 3.1% in the 2nd quarter. Perkins Capital Management Inc. now owns 25,200 shares of the medical device company's stock valued at $362,000 after acquiring an additional 750 shares during the last quarter. Institutional investors own 91.72% of the company's stock.
幾家對衝基金最近增持或減持了該公司的股份。Rhumbline Advisers在第四季度將其在心血管系統公司的股份增加了0.6%。Rhumbline Advisers現在擁有這家醫療設備公司99,634股股票，價值1,871,000美元，上個季度又購買了566股。瑞銀集團(UBS Group AG)第二季度增持了6.3%的心血管系統股票。瑞銀集團(UBS Group AG)現在持有這家醫療設備公司11,500股股票，價值16.5萬美元，上個季度又購入了679股。PNC金融服務集團(PNC Financial Services Group Inc.)在第一季度增持了32.1%的心血管系統股票。PNC金融服務集團(PNC Financial Services Group Inc.)在上個季度增持了735股後，現在持有這家醫療設備公司3,025股股票，價值6.8萬美元。伊頓·萬斯管理公司在第四季度增持了心血管系統公司5.4%的股份。在上個季度增持了749股後，伊頓·萬斯管理公司現在持有這家醫療器械公司14,547股股票，價值252,000美元。最後，珀金斯資本管理公司(Perkins Capital Management Inc.)在第二季度增持了心血管系統股份3.1%。珀金斯資本管理公司(Perkins Capital Management Inc.)在上個季度增持了750股後，現在持有這家醫療設備公司25,200股，價值36.2萬美元。機構投資者持有該公司91.72%的股票。
Cardiovascular Systems Company Profile
心血管系統公司簡介
(Get Rating)
(獲取評級)
Cardiovascular Systems, Inc, a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products.
心血管系統公司是一家醫療技術公司，在美國和國際上開發和銷售治療外周和冠狀動脈疾病的解決方案。該公司提供外周動脈疾病產品，包括基於導管的平臺，用於治療膝蓋以上和膝蓋以下的各種斑塊類型，包括鈣化斑塊，以及解決與手術、導管和藥物治療替代方案相關的各種限制；以及外周支持產品。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Cardiovascular Systems (CSII)
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- 免費獲取StockNews.com心血管系統研究報告(CSII)
- 阿徹·丹尼爾斯·米德蘭：49年增長的紅利英雄
- 全自動拖拉機會讓迪爾成為農業領域的特斯拉嗎？
- 麥格納國際是您的汽車和電動汽車一站式庫存
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat：回顧一週9/26-9/30
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.
接受《每日心血管系統》新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對心血管系統和相關公司的最新新聞和分析師評級的每日簡要摘要。